NASDAQ · KRRO
Korro Bio, Inc.
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
Loading market information…
NASDAQ · AXLA · USD
Stock price, earnings
Quote as of Jan 16, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Axcella Health Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. in June 2016. Its operations are headquartered in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Nov 10, 2021 |
| -$0.41+10.87% vs estimate |
| $0.00 |
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
$2.06+$0.07 (+3.52%)
TuHURA Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.94% below the high.
$1.12-$0.01 (-0.89%)
Reunion Neuroscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.8% below the high.
$0.26-$0.01 (-3.13%)
Applied Molecular Transport Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$0.10$0.00 (0.0%)
ObsEva S.A.’s quoted price sits in the lower half of its reported 52-week range, 95.24% below the high.
€0.21-€0.01 (-2.38%)
Celyad Oncology S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.46% below the high.
$0.25-$0.09 (-27.68%)
Notable Labs, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 94.15% below the high.
$0.02$0.00 (0.0%)
SQZ Biotechnologies Company’s quoted price sits in the lower half of its reported 52-week range, 65.71% below the high.
